Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 858 participants.
Also called NCT04437303
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 858 participants
- Sponsor
- Registry
-
NCT04437303
-
- Other papers using this trial's data
- Continuation versus Interruption of Oral Anticoagulation during TAVI
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Denmark, Ireland, Italy, Luxembourg, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT04437303. Randomized; single masking; primary purpose prevention. Start 2020-11-25 (actual); primary completion 2024-03-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)
- Condition
- Aortic Valve Disease
- Condition
- Aortic Valve Stenosis
- Condition
- Stroke
- Condition
- Bleeding
- Condition
- Vascular Complications
- Condition
- Myocardial Infarction
- Condition
- Thrombosis Embolism
- Intervention (Drug)
- Continuation of oral anticoagulants
- Intervention (Drug)
- Interruption of oral anticoagulants
- Lead sponsor
- St. Antonius Hospital
Record details
- Record id
cardio:ct-nct04437303- Content hash
c860bf9732ed5a2131b89b29f0bbbe6cfdfc8f3b121088a3122d771bc6a40d80